Estrella Immunopharma Presents Promising Phase I Data of EB103 in Relapsed/Refractory B-Cell NHL at 2026 ASTCT & CIBMTR Tandem Meetings

EMERYVILLE, Calif., Feb. 9, 2026 – Estrella Immunopharma, Inc. (Nasdaq: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing ARTEMIS targeting CD19 and CD22^®T-cell therapy for the treatment of cancer and autoimmune diseases. The company announced today that at the 2026 ASTCT^®with CIBMTR^®Positive results from the ongoing STARLIGHT-1 Phase I clinical trial were presented at the Tandem Meetings (the joint conference of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research).

This oral presentation highlighted the clinical data from the STARLIGHT-1 study, which aimed to evaluate the efficacy of EB103 (a CD19-directed ARTEMIS® T-cell therapy) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL). During the dose-escalation phase of the STARLIGHT-1 trial, EB103 demonstrated a 100% complete response (CR) rate at one month in the high-dose cohort. Notably, as of the data cutoff date, all patients who achieved CR maintained their response. The median duration of complete response (DOCR) has not yet been reached, with the duration of response ranging from 3 to 18 months.

Clinical highlights also included a complete response (CR) in a patient with primary central nervous system lymphoma (PCNSL)—a highly aggressive subtype of non-Hodgkin lymphoma (NHL) with a very poor prognosis, for which the median overall survival (OS) is only 1.5 months if left untreated.

The majority of patients enrolled in this study were considered high-risk and unsuitable for currently approved CD19 products. To date, the STARLIGHT-1 study has not reported any treatment-related serious adverse events (SAEs), further confirming EB103’s position as a safer, more accessible therapy with “best-in-class” potential for a broader patient population.

“Selection for an oral presentation at the 2026 Tandem Conference serves as strong validation of the clinical potential of EB103,” stated Naseem Esteghamat, M.D., Principal Investigator of the STARLIGHT-1 study at the University of California, Davis. “The outcomes we have observed with EB103 are truly remarkable. These patients had previously undergone multiple treatment regimens, and most were considered high-risk; nevertheless, they demonstrated significant responses to EB103 with a highly manageable toxicity profile. These clinical findings provide us with substantial confidence to continue advancing this potentially transformative therapy.”

Dr. Liu Cheng, CEO of Estrella, stated, “These data represent a significant milestone for Estrella, underscoring the potential of EB103 to address substantial unmet medical needs in the field of B-cell non-Hodgkin lymphoma (NHL). The unique design of ARTEMIS® T cells aims to overcome the safety barriers and durability limitations associated with conventional CD19 CAR-T therapies, holding promise for achieving long-term disease control in a broader patient population.”

Estrella is a clinical-stage biopharmaceutical company dedicated to developing ARTEMIS® T-cell therapies targeting CD19 and CD22 for the treatment of cancer and autoimmune diseases. Estrella’s mission is to harness the evolutionary power of the human immune system to improve the quality of life for patients with cancer and other diseases. To fulfill this mission, Estrella’s lead candidate, EB103, leverages Eureka’s ARTEMIS® technology to target CD19, a protein expressed on the surface of nearly all B-cell leukemias and lymphomas. Estrella is also developing EB104, which similarly utilizes Eureka’s ARTEMIS® technology to simultaneously target CD19 and CD22, two proteins expressed on the surface of most B-cell malignancies. For more information about Estrella, please visit www.estrellabio.com.